INTRODUCTION
============

Spinal cord injury (SCI) is a devastating event that can cause far-reaching effects on individuals' health, with further economic and social ramifications \[[@b1-inj-1836118-059]\]. The incidence rate of SCI hospitalizations was found to be 4.8 per 1,000 person-years \[[@b2-inj-1836118-059]\].

In patients with severe SCI, the micturition reflex from the spinal cord segment is released from supraspinal modulation. This reflex increases the concentration of nerve growth factor distributed in the bladder wall. Subsequently, hyperexcitability of afferent nerves and detrusor overactivity (DO) occur in the bladder \[[@b3-inj-1836118-059]\]. Then, patients often complain of lower urinary tract symptoms such as urinary frequency, urgency, and urinary incontinence (UI) \[[@b4-inj-1836118-059]\]. Therapies for neurogenic detrusor overactivity (NDO), which is a complex and multilevel process, include medications (such as anticholinergic drugs and onabotulinumtoxinA \[BoNT-A\]), surgical procedures (such as sacral nerve stimulation), functional exercises, and psychological therapies. Since the causes of NDO are diverse, therapies should be chosen on an individualized basis \[[@b5-inj-1836118-059],[@b6-inj-1836118-059]\].

In August 2011, BoNT-A was approved for patients with NDO after SCI by the U.S. Food and Drug Administration (FDA) \[[@b7-inj-1836118-059]\]. To date, many studies have focused on the efficacy and safety of BoNT-A in improving urodynamic parameters and reducing the number of UI episodes. However, the absence of high-quality studies, especially randomized controlled trials (RCTs), has made it challenging to conduct a systematic review of this issue. Therefore, the efficacy and safety of BoNT-A have remained controversial. With this in mind, the purpose of this meta-analysis was to further evaluate the efficacy and safety of BoNT-A.

MATERIALS AND METHODS
=====================

Search Strategy
---------------

We searched the PubMed, Embase, and Cochrane databases for all relevant articles published from 2001 to June 2016.The references of the retrieved studies were also reviewed. We used the following keywords: "neurogenic detrusor overactivity," "spinal cord injury," "botulinum toxin A," "BoNT-A" and "BOTOX." Articles were restricted to clinical trials.

Inclusion Criteria
------------------

All identified clinical trials were screened by 2 reviewers and had to meet the following criteria for inclusion in our analysis: (1) The participants were older than 18 years. (2) NDO was mainly caused by SCI (50% or more of participants). (3) BoNTA was administered by injection into the bladder wall. (4) The study contained accessible data on maximum cystometric capacity (MCC), volume at first involuntary detrusor contraction (VFIDC), detrusor pressure (Pdet), UI episodes, compliance, voiding volume, postvoid residual volume (PVR), maximum flow rate (Qmax), mean functional bladder capacity, the number of patients with complete dryness (CD), incidence of DO, incontinence-specific quality of life (I-QoL), and the number of patients with no involuntary detrusor contraction (IDC). (5) The full text of the study could be found. Studies not meeting any of those criteria were excluded.

Exclusion Criteria
------------------

Studies meeting any of the following criteria were excluded from this analysis: (1) The full text was not accessible. (2) It was not a clinical trial (i.e., reviews, basic science). (3) It contained duplicate data from the same trial; in such cases, where findings from the same trial were published in multiple journals, only the most useful publication was used for this analysis. (4) Studies without sufficient subjects (i.e., case reports of single cases) or accessible data were also excluded from this analysis. After the selection, we regathered all the articles, both included and excluded, to perform a confirmatory assessment of the reasons for inclusion or exclusion.

Quality Assessment
------------------

All the studies were graded according to the Cochrane Handbook for Systematic Reviews of Interventions 5.1. Eight entries represented 5 biases: selection bias, performance bias, detection bias, attrition bias, and reporting bias. Random sequence generation, double-blinding of participants and studiers, and double-blinding of outcomes indicated low risk. Allocation concealment, incomplete outcome data addressed, and selective reporting corresponded to high risk. Based on these criteria, all studies were classified using 3 grades, from A to C: (A) If all the key domains, and most information, met the low-risk criteria, the study was seen as having a low risk of bias. (B) If ≥1 key domains had an unclear risk of bias, and most information was at low or unclear risk, the study was viewed as having an unclear risk of bias. (C) If ≥1 key domains met the high-risk criteria and some information, with a significant influence on the results, was at a high risk of bias, the study was considered to have a high risk of bias \[[@b8-inj-1836118-059]\].

Data Extraction
---------------

Two reviewers read all the full texts, including the content of the publications and abstracts. The following information was collected from all included studies: (1) the first author's name and the year of publication; (2) the nations of the participants; (3) the sample size and numbers of each group; (4) the dose and location of administration; (5) baseline, index after at least 1 injection, or changes in urodynamic parameters and clinical outcomes; and (6) the type and number of adverse events (AEs). If there was controversy over any aspects of the studies, a third reviewer was invited to review the study. If necessary, a fourth reviewer was included.

Statistical Analysis
--------------------

All data were recorded in an Excel spreadsheet by 2 individual reviewers. After this procedure, Review Manager ver. 5.3 (Cochrane Collaboration, Oxford, UK) was used to carry out the meta-analysis. In this process, the mean difference (MD) and 95% confidence interval (CI) were calculated using the software. Meanwhile, I^2^ was used to measure heterogeneity across trials. If I^2^ did not reach 50%, we chose a fixed-effects model. When I^2^ exceeded 50%, a random-effects model was more suitable. All types of AEs and the overall number of each AE in both the experimental and control groups were recorded.

RESULTS
=======

Characteristics of Individual Studies
-------------------------------------

[Fig. 1](#f1-inj-1836118-059){ref-type="fig"} shows the process of selection in this meta-analysis. After reading the abstracts and full texts, the 70 studies excluded involve (1) 64 excluded based on title and abstracts; (2) 2 excluded due to absent of full text; (3) 4 reviews, cases or editorials in [Fig. 1](#f1-inj-1836118-059){ref-type="fig"}. The remaining 24 studies involve 7 excluded (3 repetition and 4 no accessible data) and 17 eligible studies included. Ultimately, 17 studies with 1,455 patients were included in the meta-analysis. Eleven studies were RCTs. Eight studies investigated BoNT-A versus placebo, 4 investigated BoNT-A doses of 200 U versus 300 U, 2 investigated injections into the detrusor versus submucosa, and 2 investigated sparing the trigone versus avoiding the trigone. According to the Cochrane Handbook for Systematic Reviews of Interventions 5.1, 5 studies were evaluated as grade A, 5 as grade B, and 7 as grade C. The primary characteristics and quality assessment of the included studies are shown in [Table 1](#t1-inj-1836118-059){ref-type="table"}. The funnel plot provided an estimation of the publication bias of the studies, and no evidence of bias was found ([Fig. 2](#f2-inj-1836118-059){ref-type="fig"}).

The Efficacy of BoNT
--------------------

### BoNT-A versus placebo

Five studies involving 961 participants included data for a comparison of BoNT-A versus placebo \[[@b9-inj-1836118-059]-[@b14-inj-1836118-059]\]. Compared with placebo, BoNT-A increased the MCC (MD, 134.75; 95% CI, 105.06--164.44; P\<0.00001), VFIDC (MD, 163.42; 95% CI, 96.41--230.43; P\<0.00001), and the number of participants with no IDC and decreased Pdet (MD, -30.48; 95% CI, -38.38 to -22.58; P\<0.00001) and UI episodes (MD, -12.45; 95% CI, -19.90 to -5.00; P=0.001). However, the PVR (MD, 95.97; 95% CI, 60.10--131.84; P\<0.00001) increased more in the BoNT-A group than in the placebo group ([Fig. 3](#f3-inj-1836118-059){ref-type="fig"}).

### Baseline versus after treatment

Ten studies involving 386 participants included data representing baseline versus posttreatment outcomes \[[@b10-inj-1836118-059],[@b15-inj-1836118-059]-[@b24-inj-1836118-059]\]. The results presented above were confirmed in the comparison between baseline and posttreatment values ([Fig. 4](#f4-inj-1836118-059){ref-type="fig"}) \[[@b9-inj-1836118-059]-[@b21-inj-1836118-059],[@b24-inj-1836118-059],[@b25-inj-1836118-059]\]. In addition, BoNT-A was effective in increasing the voiding volume (MD, 51.01; 95% CI, 37.75--64.27; P\<0.00001), compliance (MD, -14.34; 95% CI, -23.18 to -5.49; P=0.001), and the number of patients with CD (odds ratio \[OR\], 0.02; 95% CI, 0.00--0.17; P=0.0003), reduced Qmax (MD, 3.34; 95% CI, 2.17--4.51; P\<0.00001), and reduced incidence of DO (OR, 64.27; 95% CI, 12.17--339.28; P\<0.00001) ([Fig. 5](#f5-inj-1836118-059){ref-type="fig"}).

Five other studies presented the effects of BoNT-A on I-QoL \[[@b14-inj-1836118-059],[@b16-inj-1836118-059],[@b18-inj-1836118-059],[@b20-inj-1836118-059],[@b23-inj-1836118-059]\]. They were divided into 2 groups because they used different tools to evaluate I-QoL: a 22-item questionnaire and the International Prostatic Symptom Score questionnaire. Their results showed that BoNT-A was effective in improving IQoL, and this improvement was significant ([Fig. 5F](#f5-inj-1836118-059){ref-type="fig"}).

### BoNT-A dose: 200 U versus 300 U

Four studies involving 919 participants included data comparing doses of 200 U of BoNT-A versus 300 U \[[@b9-inj-1836118-059],[@b12-inj-1836118-059],[@b14-inj-1836118-059],[@b18-inj-1836118-059],[@b25-inj-1836118-059]\]. No significant difference was found between 200 U and 300 U of BoNT-A in mean functional bladder capacity (MD, 24.5; 95% CI, -60.51 to 12.02; P\<0.19), MCC (MD, -2.32; 95% CI, -36.19 to 31.56; P\<0.89), compliance (MD, 3.10; 95% CI, -7.47 to 13.67; P\<0.57), PVR (MD, -79.85; 95% CI, -120.41 to -39.29; P=0.0001), Pdet (MD, -7.07; 95% CI, -15.48 to 1.34; P\<0.10), UI episodes (MD, -1.27; 95% CI, -6.82 to 4.27; P=0.65) and the number of patients with no IDC (MD, 0.77; 95% CI, 0.53--1.12; P=0.18) ([Fig. 6](#f6-inj-1836118-059){ref-type="fig"}).

### Injections into the detrusor versus submucosa

Two studies involving 55 participants included data comparing injections into the detrusor versus submucosa \[[@b19-inj-1836118-059],[@b24-inj-1836118-059]\]. No significant difference was found in mean functional bladder capacity (MD, -54.26; 95% CI, -81.91 to -26.61; P=0.0001), VFIDC (MD, -37.69; 95% CI, -83.60 to 8.22; P\<0.00001), Pdet (MD, -7.99; 95% CI, -21.98 to 6.00; P=0.26) and UI episodes (MD, -1.21; 95% CI, -5.30 to 2.88; P=0.56) ([Fig. 7](#f7-inj-1836118-059){ref-type="fig"}).

Safety
------

We recorded all types of AEs and their proportions \[[@b9-inj-1836118-059]-[@b28-inj-1836118-059]\]. The chi-square test was used to evaluate differences between pairs of groups. [Table 2](#t2-inj-1836118-059){ref-type="table"} lists the top 10 AEs, including symptomatic urinary tract infection, urinary retention, hematuria, diarrhea, nausea, constipation, pyrexia, fatigue, headache, and autonomic dysreflexia. Nearly half of the AEs were not considered to have been treatment-related. Others could recover spontaneously or with only symptomatic treatment, and no AEs were life-threatening.

DISCUSSION
==========

The neurotoxin Botulinum toxin, first described by van Ermengem in 1897, was extracted from the bacterium *Clostridium botulinum* \[[@b29-inj-1836118-059],[@b30-inj-1836118-059]\]. BoNT-A, as a subtype, received FDA approval for the clinical treatment of NDO in 2011 \[[@b31-inj-1836118-059]\]. BoNT-A inhibits neurotransmitter release from efferent nerve and sensory nerve endings. After BoNT-A injections, the expression of bladder muscarinic receptors M2 and M3 is reduced in humans with NDO \[[@b32-inj-1836118-059]\]. For the above reasons, BoNT-A can induce the inhibition of DO and cause Pdet to decrease. Recent studies have reported it to have significant benefits on urodynamic parameters and clinical indices \[[@b33-inj-1836118-059]\].

According to this meta-analysis, compared with baseline, BoNT-A was effective in increasing MCC, VFIDC, the voiding volume, compliance, I-QoL, the number of patients with CD and no IDC, and in decreasing Pdet, UI episodes, Qmax, and the incidence of DO \[[@b10-inj-1836118-059],[@b15-inj-1836118-059]-[@b24-inj-1836118-059]\]. Meanwhile, this meta-analysis further indicated that compared with placebo, BoNT-A was effective in increasing MCC, VFIDC, and the number of patients with no IDC, and in decreasing Pdet and UI episodes during 18 months of follow-up \[[@b8-inj-1836118-059]-[@b14-inj-1836118-059]\]. However, PVR was found to increase. The reason for this is that as MCC and VFIDC increased, the residual volume after voiding also increased. Additionally, since the dose used in clinical therapy remained controversial, our review mainly focused on comparing the most frequent doses (200 U and 300 U) \[[@b31-inj-1836118-059]\]. Both doses were comparably effective in terms of outcomes for mean functional bladder capacity, MCC, compliance, PVR, Pdet, UI episodes, and the number of patients with no IDC \[[@b9-inj-1836118-059],[@b12-inj-1836118-059],[@b14-inj-1836118-059],[@b18-inj-1836118-059],[@b25-inj-1836118-059]\]. Likewise, no significant difference was found between injection into the detrusor versus the submucosa in terms of mean functional bladder capacity, VFIDC, Pdet, and UI episodes \[[@b19-inj-1836118-059],[@b24-inj-1836118-059]\].

In addition to the above-presented results, 2 RCTs involving 127 participants compared injection locations (sparing the trigone and excluding the trigone). One study compared 160 U of BoNT-A injected into the bladder wall combined with 40 U into the trigone versus the injection of 200 U into the bladder wall, avoiding the trigone \[[@b16-inj-1836118-059]\]. Both methods increased the number of patients with CD (+13 vs. +5, P=0.01), improved IQoL (26.01±11.56 vs. 18.75±15.18), decreased UI episodes (-5.22±0.91 vs. -4.68±1.06, P=0.01), and Pdet (-33.34±20.27 vs. -28.02±15.18, P=0.04). However, sparing the trigone was considered preferable \[[@b11-inj-1836118-059]\]. The other study compared 200 U injected into the detrusor combined with 100 U into the trigone versus 300 U injected into the detrusor, avoiding the trigone \[[@b23-inj-1836118-059]\]. Sparing the trigone was more obviously preferable in terms of increasing patients with CD (+12 vs. +6, P\<0.001) and decreasing UI episodes (0.98±0.45 vs. 2.38±0.79, P\<0.001). However, no significant differences were found in MCC (384.6±49.7 vs. 406.5±55.4, P=0.22), Pdet (35.0±3.6 vs. 36.9±5.1, P=0.21), I-QoL (2.22±0.55 vs. 2.22±0.65, P=0.44) \[[@b22-inj-1836118-059]\]. Considering the diversity of doses in the 2 studies, further research is needed.

Nevertheless, there were some limitations of our analysis. We considered conducting subgroup analyses based on quality assessment, as shown in [Table 1](#t1-inj-1836118-059){ref-type="table"}. However, there were not enough data in each subgroup for such an analysis. Therefore, considering the same standard of quality assessments for all the studies and in order to avoid repeating our analyses, we summarized the primary characteristics and quality assessment results of all the included studies in [Table 1](#t1-inj-1836118-059){ref-type="table"}. Furthermore, it seemed to be better to evaluate the MD of differences instead of the MD of values when comparing the effect of BoNT-A on baseline versus posttreatment values. However, most of the raw data from the included studies only provided the values after treatment, instead of the difference between baseline and after treatment. Therefore, we only evaluated the MDs.

In addition, heterogeneity could be generated by the subjects chosen, the location and dose of each site, and the loss of some negative data. Heterogeneity can be reduced by applying conscientious and rigorous procedures and sensitivity analyses, but it cannot be eliminated. Meanwhile, due to differences in the follow-up periods, the long-term effects were somewhat difficult to evaluate. Furthermore, the data in the studies included in this meta-analysis were insufficient to determine which dose and injection site were better for patients, so more highquality prospective trials are still needed \[[@b8-inj-1836118-059]\].

In conclusion, BoNT-A is effective and safe in treating NDO after SCI in the short term. There were no significant differences between 200 U or 300 U of BoNT-A and between injecting into the detrusor or submucosa. More high-quality and refined RCTs are needed.
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![Forest plots comparing the effects of onabotulinumtoxinA (BoNT-A) versus placebo on maximum cystometric capacity (MCC) (A), volume at first involuntary detrusor contraction (VFIDC) (B), detrusor pressure (Pdet) (C), urinary incontinence (UI) episodes (D), number of patients with no involuntary detrusor contraction (IDC) (E), and postvoid residual volume (PVR) (F). SD, standard deviation; CI, confidence interval; df, degrees of freedom.](inj-1836118-059f3){#f3-inj-1836118-059}

![Forest plots comparing the effect of onabotulinumtoxinA (BoNT-A) on baseline values versus posttreatment values of maximum cystometric capacity (MCC) (A), volume at first involuntary detrusor contraction (VFIDC) (B), detrusor pressure (Pdet) (C), urinary incontinence (UI) episodes (D), number of patients with no involuntary detrusor contraction (IDC) (E), and postvoid residual volume (PVR) (F). SD, standard deviation; CI, confidence interval; df, degrees of freedom.](inj-1836118-059f4){#f4-inj-1836118-059}

![Forest plots comparing the effect of onabotulinumtoxinA (BoNT-A) on baseline values versus posttreatment values of voiding volume (A), compliance (B), maximum flow rate (Qmax) (C), incidence of detrusor overactivity (DO) (D), number of patients with complete dryness (CD) (E), and incontinence-specific quality of life (I-QoL) (F). SD, standard deviation; CI, confidence interval; df, degrees of freedom.](inj-1836118-059f5){#f5-inj-1836118-059}

![Forest plots comparing the difference between 200 U and 300 U of onabotulinumtoxinA (BoNT-A) on mean functional bladder capacity (A), maximum cystometric capacity (MCC) (B), compliance (C), postvoid residual volume (PVR) (D), detrusor pressure (Pdet) (E), urinary incontinence (UI) episodes (F), and number of patients with no involuntary detrusor contraction (IDC) (G). SD, standard deviation; CI, confidence interval; df, degrees of freedom.](inj-1836118-059f6){#f6-inj-1836118-059}

![Forest plots comparing the difference between injections into the detrusor versus submucosa on mean functional bladder capacity (A), volume at first involuntary detrusor contraction (VFIDC) (B), detrusor pressure (Pdet) (C), and urinary incontinence (UI) episodes (D). SD, standard deviation; CI, confidence interval; df, degrees of freedom.](inj-1836118-059f7){#f7-inj-1836118-059}

###### 

Primary characteristics and quality assessment

  Study                                                             Sample size   Study design   Country                     Age (yr)        Time since SCI    Induction                                                                                             Outcome measures                                        Follow-up (mo)   Quality assessment^[a)](#tfn1-inj-1836118-059){ref-type="table-fn"}^
  ----------------------------------------------------------------- ------------- -------------- --------------------------- --------------- ----------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------- ---------------- ----------------------------------------------------------------------
  Ginsberg, 2013 \[[@b9-inj-1836118-059]\]                          310           Prospective    International multicenter   41.5 ± 14.5     10.9 ± 11.4 yr    200 U, 300 U into the detrusor avoiding the trigone, +30 sites                                        MCC, Pdet, no. with no IDC                              13               A
  Jia, 2013 \[[@b10-inj-1836118-059]\]                              41            Prospective    China                       36.0 ± 8.8      21.5 ± 17.3 mo    300 U into the detrusor sparing the trigone, +30 sites                                                Compliance, incidence of DO                             N                C
  Apostolidis, 2013 \[[@b11-inj-1836118-059]\]                      73            Prospective    International multicenter   33.6 ± 10.8     31.4 mo           200 U into the detrusor avoiding the trigone, +30 sites                                               MCC, VFIDC, Pdet, compliance                            13.5             B
  Sussman, 2013 \[[@b12-inj-1836118-059],[@b13-inj-1836118-059]\]   121           Prospective    International multicenter   43.1 ± 15.2     8.1 ± 7.1 yr      200 U, 300 U into the detrusor avoiding the trigone, +30 sites                                        MCC, VFIDC, Pdet, UI episodes, PVR                      13               A
  Ginsberg, 2012 \[[@b14-inj-1836118-059]\]                         416           Prospective    International multicenter   46 ± 13         14 ± 9 yr         2 00 U, 300 U into the detrusor sparing the trigone, +30 sites                                        MCC, Pdet, UI episodes, no. with no IDC, I-QoL, PVR     13               A
  Chen, 2016 \[[@b15-inj-1836118-059]\]                             30            Prospective    Germany                     48.2 ± 18.41    NA                300 U into the detrusor, +30 sites                                                                    PVR, voiding volume, Qmax                               18               C
  Hui, 2016 \[[@b16-inj-1836118-059]\]                              91            Prospective    China                       29.83 ± 11.77   20.04 ± 6.56 mo   160 into the wall and 40 into the trigone vs. 200 into the wall, avoiding the trigone, +30 sites      Pdet, voiding volume, VFIDC, I-QoL, UI episodes, etc.   3                B
  Sengoku, 2015 \[[@b17-inj-1836118-059]\]                          19            Prospective    Japan                       41.1 ± 14.2     11 y+ 5 mo        200 U into the subepithelial bladder wall sparing the trigone, +30 sites                              UI episodes, incidence of DO                            12               C
  Chen, 2014 \[[@b18-inj-1836118-059]\]                             72            Prospective    Taiwan                      41.5            8.7 ± 8.1 yr      200 U, 300 U into the detrusor, avoiding the trigone, +30 sites                                       PVR, voiding volume, Qmax, I-QoL, compliance            12               C
  Krhut, 2012 \[[@b19-inj-1836118-059]\]                            32            Prospective    International multicenter   20-48           NA                300 U into the detrusor and suburothelial, +30 sites                                                  MCC, VFIDC, Pdet, voiding volume, etc.                  3                B
  Chen, 2011 \[[@b20-inj-1836118-059]\]                             38            Prospective    Taiwan                      40.1 ± 12.4     10.3 yr           300 U into the detrusor sparing the trigone, +40 sites                                                PVR, Qmax, I-QoL                                        6                C
  Gamé, 2008 \[[@b21-inj-1836118-059]\]                             30            Prospective    France                      39.4 ± 12.1     13.3 ± 19.1 yr    300 U into the detrusor sparing the trigone, +30 sites                                                VFIDC, incidence of DO                                  6                C
  Klaphajone, 2005 \[[@b22-inj-1836118-059]\]                       10            Prospective    Thailand                    32.5            55.5 mo           300 U into the detrusor sparing the trigone, +15--30 sites                                            Compliance,                                             9                C
  Abdel-Meguid, 2010 \[[@b23-inj-1836118-059]\]                     36            Prospective    Egypt                       25 ± 3.1        31 ± 13.7 mo      300 U into the detrusor avoiding the trigone vs. 200 U into the detrusor and 100 U into the trigone   Mean volume of first reflex, UI episodes, etc.          4.5              B
  Šámal, 2013 \[[@b24-inj-1836118-059]\]                            23            Prospective    Liberec                     20 -58          47 mo             300 U into the detrusor avoiding the trigone +submucosa, +30 sites                                    VFIDC, Pdet, UI episodes                                3                B
  Herschorn, 2011 \[[@b25-inj-1836118-059]\]                        57            Prospective    Canada                      42.8            7.0 ± 6.8 yr      300 U into the detrusor sparing the trigone, +30 sites                                                UI episodes                                             15               A
  Schurch, 2007 \[[@b26-inj-1836118-059]-[@b28-inj-1836118-059]\]   56            Prospective    Switzerland                 41.6 ± 12.8     63 mo             200 U, 300 U into the detrusor sparing the trigone, +30 sites                                         AEs                                                     6                A

SCI, spinal cord injury; MCC, maximum cystometric capacity; Pdet, detrusor pressure; IDC, involuntary detrusor contraction; DO, detrusor overactivity; VFIDC, volume at first involuntary detrusor contraction; UI, urinary incontinence; PVR, postvoid residual volume; I-QoL, incontinence-specific quality of life; Qmax, maximum flow rate; AEs, adverse events; NA, not applicable.

Quality assessment: (A) If all the key domains, and most information, met the low-risk criteria, the study was seen as having a low risk of bias. (B) If ≥1 key domains had an unclear risk of bias, and most information was at low or unclear risk, the study was viewed as having an unclear risk of bias. (C) If ≥1 key domains met the high-risk criteria and some information, with a significant influence on the results, was at a high risk of bias, the study was considered to have a high risk of bias.

###### 

Complications of BoNT-A and placebo

  Adverse event           BoNT-A            Placebo           P-value^[a)](#tfn2-inj-1836118-059){ref-type="table-fn"}^
  ----------------------- ----------------- ----------------- -----------------------------------------------------------
  Symptomatic UTI         432/861 (50.17)   160/425 (37.65)   0.00002
  Urinary retention       150/732 (20.49)   15/409 (3.67)     0.00000
  Hematuria               57/861 (6.62)     15/425 (3.53)     0.02334
  Diarrhea                41/732 (5.60)     19/409 (4.65)     0.48799
  Nausea                  40/732 (5.46)     8/409 (1.96)      0.00464
  Constipation            38/732 (5.19)     18/409 (4.40)     0.55348
  Pyrexia                 38/761 (4.99)     16/396 (4.04)     0.34073
  Fatigue                 35/704 (4.97)     13/380 (3.42)     0.23639
  Headache                34/732 (4.64)     15/409 (3.67)     0.43487
  Autonomic dysreflexia   29/776 (3.74)     2/380 (0.53)      0.00150

Values are presented as number (%).

BoNT-A, onabotulinumtoxinA; UTI, urinary tract infection.

P-values were the outcomes of the chi-square tests for independence of each adverse event between the 2 groups.

[^1]: Guang-Ping Li and Xiao-Yan Wang contributed equally to this study as co-first authors.
